Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Ming Yu Pharmaceutical (明宇制药) Pre-IPO Quick Comment: Meaningful Improvement to Incumbents

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Ming Yu Pharmaceutical / Equity Capital Markets

<ul>
<li>Ming Yu Pharmaceutical, a China-based clinical-stage biotech company, is seeking a Hong Kong Chapter 18A listing. MS, BOA, and CITIC are the joint sponsors.</li>
<li>In our previous note, we looked at the company's core products MHB018A and MHB036C, as well as its management and investor backings.</li>
<li>In this note, we look at the developments in the company's assets and the competitive landscape.</li>
</ul>


Ming Yu Pharmaceutical, a China-based clinical-stage biotech company, is seeking a Hong Kong Chapter 18A listing. MS, BOA, and CITIC are the joint sponsors.
In our previous note, we looked at the company's core products MHB018A and MHB036C, as well as its management and investor backings.
In this note, we look at the developments in the company's assets and the competitive landscape.


Ming Yu (明宇制药) Pre-IPO: Prospectus Update Suggests Mixed Views Across Products